The next debate on embryo science
By Editorial,
Nature Biotechnology
| 08. 02. 2021
The International Society for Stem Cell Research has called for broad public dialogue on the ethics of human embryo research beyond 14 days post-fertilization. National jurisdictions should seize the moment.
A longstanding prohibition against culturing human embryos for more than 14 days is now open for discussion, according to revised research guidelines released in May by the International Society for Stem Cell Research (ISSCR). The society’s change in position was prompted by recent advances in embryo culture methods that promise to deepen understanding of human development at the stage when the embryo implants in the uterus—knowledge that may lead to new therapies for infertility and miscarriage. The ISSCR is to be commended for encouraging ethical reflection on extending the 14-day rule before the world is caught off guard by an embryo experiment that goes beyond the accepted time frame. It is now up to interested parties in national scientific, political, ethics and religious communities to take up the ISSCR’s challenge.
In 1978, the birth of the first baby created through in vitro fertilization (IVF) was met with a storm of controversy. IVF provoked deep concerns and anxieties about the wisdom of tampering with the natural order of reproduction. Once human procreation was unlinked from coitus, impossible things became possible: women...
Related Articles
Alice Wong, founder of the Disability Visibility Project, MacArthur Genius, liberationist, storyteller, writer, and friend of CGS, died on November 14. Alice shone a bright light on pervasive ableism in our society. She articulated how people with disabilities are limited not by an inability to do things but by systemic segregation and discrimination, the de-prioritization of accessibility, and the devaluation of their lives.
We at CGS learned so much from Alice about disability justice, which goes beyond rights...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Heidi Ledford, Nature | 10.31.2025
Late last year, dozens of researchers spanning thousands of miles banded together in a race to save one baby boy’s life. The result was a world first: a cutting-edge gene-editing therapy fashioned for a single person, and produced in...